Ma:nyo Ac Rescue Ampoule Spot Patch
Everything behind the verdicts on this product: the rule that fired for each concern, the three answers and the documents they rest on, every study on the row with the date it was opened, and the versions of the tables that produced them. Nothing here is edited by hand; it is generated from the same records the verdicts are.
The scaleRecommendedGoodSupportingEarly evidenceNot for thisAvoidhow it works
Engine 5.2.0 · rules 0.5.1 · evidence table ev-2026.10-r231 · computed October 13, 2026 · how we decide · the evidence table · the anchors
for Acne
Salicylic Acid is an approved or monograph active for acne; this pad carries it, though the concentration is not declared.
A first-line active — approved, monograph-listed or named in current guidelines — at an effective strength, with no trigger for the concern.
- Rule
- R3 → Strong choice. A first-line active (approved, monograph-listed or named in a current guideline); at a plausible but undeclared level.
q1 = first-line · q2 = plausible
Why this rule exists: Undeclared but plausibly dosed (top-third INCI position, or a potent sub-1% active) — the verdict stands, and the sentence says what disclosure would add. A declared figure below range would have been sub-threshold.
Rule R3 decided 570 verdicts across the catalog; “Strong choice” is the verdict on 1,475 of 45,446. The full register. - Carrying active
- Salicylic Acid
- 1 · Standing
- First-line — a regulator recognises it for this use; trials support it
Document: § 333.310 Acne active ingredients. (U.S. Food and Drug Administration — 21 CFR Part 333 Subpart D (Topical Acne Drug Products), Code of Federal Regulations via GovInfo), opened July 27, 2026 - 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
Studied range: 0.5–2%, from the OTC monograph or label; judge it after about 6 weeks - 3 · Tolerability
- Gentle
- Evidence dots
- Moderate evidence
Row checked against its sources on July 27, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 25, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Guidelines of care for the management of acne vulgaris — Journal of the American Academy of Dermatology (2024), opened July 16, 2026
- 2024 AAD Acne Vulgaris Clinical Guideline Summary — Guideline Central (2024), opened July 16, 2026
- Inside the 2024 AAD Acne Guidelines: New Therapies Join Old Standbys — MDedge (2024), opened July 16, 2026
← Back to the verdict All acne products → Disclose a concentration or correct a fact →
No category-job specification exists for this category yet, so there is no job reading.
Listed for Acne Scarring, with no verdict: the actives here have no evidence row for that concern yet. That is a gap in our table, not a mark against the product.
- Acne Scarring: The actives here (Film Formers & Texture Polymers, Salicylic Acid, Tea Tree Oil, Botanical Extracts) are in the research queue for acne scarring; no verdict until their rows are written.
A verdict is Dermington’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Every rule is public and the same for every product; a brand cannot buy a reading. How we decide · what has changed · disclaimer.